Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 149

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 149
---
 Contents

Notice of Annual Meeting of Stockholders To Be Held on Wednesday, March 12, 2025 Your vote is important, whether or not you expect to attend the Annual Meeting of Stockholders. Stockholders of record are urged to vote via the Internet or telephone as instructed, or if you are voting by mail, to mark, sign and date and promptly return the proxy in the postage-prepaid return envelope provided. Voting promptly will help avoid the additional expense of further solicitation to assure a quorum at the meeting. Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on Thursday, March 12, 2025: You may access the following proxy materials at www.proxyvote.com before the meeting and www.virtualshareholdermeeting.com/ ARWR2025 during the meeting. • Notice of the 2025 Annual Meeting of Stockholders; • Company’s 2025 Proxy Statement; • Company’s Annual Report on Form 10-K for the year ended September 30, 2024; and • Form of Proxy Card TO THE STOCKHOLDERS OF ARROWHEAD PHARMACEUTICALS, INC.: NOTICE IS HEREBY GIVEN that the 2025 Annual Meeting of Stockholders of Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Arrowhead”), will be held on Wednesday, March 12, 2024, at 10:00 a.m., Pacific time (the “Annual Meeting”). This year’s meeting will be a completely “virtual” meeting of stockholders. You can attend the Annual Meeting online, vote your shares electronically, and submit your questions during the Annual Meeting by visiting www.virtualshareholdermeeting.com/ARWR2025. Prior to the Annual Meeting, you will be able to vote at www.proxyvote.com. The Annual Meeting will be held for the purpose of considering and voting upon the following proposals, as more fully described in the accompanying Proxy Statement: 1. To elect the eight directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected; 2. To conduct an advisory (non-binding) vote to approve executive compensation; 3. To conduct an advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation; 4. To ratify the selection of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2025; and 5. To trans